Shandong Kexing Bioproducts Co. Ltd. A
Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral ther… Read more
Shandong Kexing Bioproducts Co. Ltd. A (688136) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.019x
Based on the latest financial reports, Shandong Kexing Bioproducts Co. Ltd. A (688136) has a cash flow conversion efficiency ratio of -0.019x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-32.71 Million) by net assets (CN¥1.72 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shandong Kexing Bioproducts Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Shandong Kexing Bioproducts Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shandong Kexing Bioproducts Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shandong Kexing Bioproducts Co. Ltd. A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Urban Company Limited
NSE:URBANCO
|
0.012x |
|
Schoeller-Bleckmann Oilfield Equipment Aktiengesellschaft
PINK:SBOEF
|
0.065x |
|
Tus-Sound Environmental Resources Co Ltd
SHE:000826
|
0.045x |
|
Nanjing Chemical Fibre Co Ltd
SHG:600889
|
-0.100x |
|
Prime Medicine, Inc. Common Stock
NASDAQ:PRME
|
-0.217x |
|
Ridley Corporation Limited
PINK:RIDYF
|
0.068x |
|
Boss Energy Ltd
AU:BOE
|
0.077x |
|
Apollo Micro Systems Limited
NSE:APOLLO
|
1.232x |
Annual Cash Flow Conversion Efficiency for Shandong Kexing Bioproducts Co. Ltd. A (2017–2024)
The table below shows the annual cash flow conversion efficiency of Shandong Kexing Bioproducts Co. Ltd. A from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.64 Billion | CN¥106.67 Million | 0.065x | +221.79% |
| 2023-12-31 | CN¥1.63 Billion | CN¥-87.14 Million | -0.053x | -12.34% |
| 2022-12-31 | CN¥1.81 Billion | CN¥-85.89 Million | -0.048x | -196.66% |
| 2021-12-31 | CN¥1.91 Billion | CN¥94.01 Million | 0.049x | -14.99% |
| 2020-12-31 | CN¥1.83 Billion | CN¥105.93 Million | 0.058x | +667.13% |
| 2019-12-31 | CN¥696.34 Million | CN¥5.25 Million | 0.008x | -94.12% |
| 2018-12-31 | CN¥494.46 Million | CN¥63.44 Million | 0.128x | -57.99% |
| 2017-12-31 | CN¥212.24 Million | CN¥64.81 Million | 0.305x | -- |